Biotron logo

BIT - Biotron Share Price

A$0.069 -0.0  -1.4%

Last Trade - 26/02/21

Micro Cap
Market Cap £27.2m
Enterprise Value £22.9m
Revenue £451k
Position in Universe 1086th / 1832
Unlock BIT Revenue
Relative Strength (%)
1m -13.3%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -54.0%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
1.67 1.55 1.66 1.62 1.07 0.80 -13.6%
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 30 June 2020, BiotronLimited revenues decreased 25% to A$803K. Net lossincreased from A$1.6M to A$3.6M. Revenues reflect adecrease in demand for the Company's products and servicesdue to unfavorable market conditions. Higher net lossreflects Employee & Director Expenses increase of 9% toA$876K (expense), Interest income decrease of 22% to A$69K(income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


BIT Revenue Unlock BIT Revenue

Net Income

BIT Net Income Unlock BIT Revenue

Normalised EPS

BIT Normalised EPS Unlock BIT Revenue

PE Ratio Range

BIT PE Ratio Range Unlock BIT Revenue

Dividend Yield Range

BIT Dividend Yield Range Unlock BIT Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
BIT EPS Forecasts Unlock BIT Revenue
Profile Summary

Biotron Limited is an Australia-based biotechnology company. The Company is engaged in the funding and management of intermediate, and applied biotechnology research and development projects. The Company is focused on the ongoing clinical development of its antiviral platform. The Company's lead antiviral drug, BIT225 is in mid-stage clinical development with approximately eight clinical trials completed. The Company has conducted clinical trails in human immunodeficiency virus-1 (HIV-1), hepatitis C virus (HCV) and HIV-1/HCV co-infected population. The clinical trials showed that BIT225 targets and reduces levels of HIV-1 residing in long-lived monocyte/macrophage reservoirs. BIT225 has clinical antiviral activity against both HIV-1 and HCV. BIT225 is pan-genotypic and is active against all HCV genotypes, including GT3. The Company designs and develops drugs that target a class of virus protein known as viroporins. Its earlier stage programs include Dengue, Influenza and others.

Last Annual June 30th, 2020
Last Interim June 30th, 2020
Incorporated February 23, 1999
Public Since January 24, 2001
No. of Shareholders: 7,632
No. of Employees: 4
Sector Healthcare
Industry Biotechnology & Medical Research
Exchange Australian Stock Exchange - SEATS
Shares in Issue 701,932,713
Free Float (0.0%)
Eligible for
BIT Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for BIT
Upcoming Events for BIT
Frequently Asked Questions for Biotron
What is the Biotron share price?

As of 26/02/21, shares in Biotron are trading at A$0.069, giving the company a market capitalisation of £27.2m. This share price information is delayed by 15 minutes.

How has the Biotron share price performed this year?

Shares in Biotron are currently trading at A$0.069 and the price has moved by -40% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Biotron price has moved by -41.76% over the past year.

What are the analyst and broker recommendations for Biotron?

There are no analysts currently covering Biotron.

When will Biotron next release its financial results?

Biotron is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the Biotron dividend yield?

Biotron does not currently pay a dividend.

Does Biotron pay a dividend?

Biotron does not currently pay a dividend.

When does Biotron next pay dividends?

Biotron does not currently pay a dividend.

How do I buy Biotron shares?

To buy shares in Biotron you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Biotron?

Shares in Biotron are currently trading at A$0.069, giving the company a market capitalisation of £27.2m.

Where are Biotron shares listed? Where are Biotron shares listed?

Here are the trading details for Biotron:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: BIT
What kind of share is Biotron?

Based on an overall assessment of its quality, value and momentum, Biotron is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Biotron share price forecast 2021?

We were not able to load any forecast data for Biotron.

How can I tell whether the Biotron share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biotron. Over the past six months, the relative strength of its shares against the market has been -33.23%. At the current price of A$0.069, shares in Biotron are trading at -21.8% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Biotron PE Ratio?

We were not able to find PE ratio data for Biotron.

Who are the key directors of Biotron?

Biotron's management team is headed by:

Michelle Miller - CEO
Peter Nightingale - SEC
Michael Hoy - NEC
Susan Pond - NID
Robert Thomas - NID
Stephen Locarnini - DRC
Stephen Becker - OTH
Who are the major shareholders of Biotron?

Here are the top five shareholders of Biotron based on the size of their shareholding:

Jey Investment Pty. Ltd. Corporation
Percentage owned: 2.06% (14.4m shares)
Dulhunty (Angela Fay) Individual Investor
Percentage owned: 1.42% (10.00m shares)
Hoy (Michael John) Individual Investor
Percentage owned: 1.33% (9.35m shares)
Armco Barriers Pty. Ltd. Corporation
Percentage owned: 1.11% (7.80m shares)
DNS Accounting and Law Consultancy Pty. Ltd. Corporation
Percentage owned: 1.1% (7.75m shares)
Similar to BIT
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.